en · de · es · fr · pt
sr9009-notes.peptides9000.com › Guide › Mechanism And Preclinical Findings — Background and Details

Mechanism And Preclinical Findings — Background and Details

By Editorial Desk · published 2025-07-08 · last reviewed 2025-07-30 · Guide

LC-MS/MS raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

This page was last updated on 2025-07-30 and is reviewed periodically as new material appears.

Mechanism and Preclinical Findings

SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.

Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.

SR9009 Background and Receptor Mechanism

SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.

SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.

Sr9009 at a glance

PropertyValueNotes
Chemical classSynthetic REV-ERB agonistSmall molecule; not a steroid or peptide.
Primary targetsNR1D1 and NR1D2Also known as REV-ERBα and REV-ERBβ.
Studied routesIntraperitoneal in rodentsOral bioavailability in humans is not established.
Human approvalNo approved therapeutic indicationNo recognized clinical use.
Key uncertaintyHuman physiological effectsPreclinical findings may not translate.

Analytical Detection and Storage

Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.

Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.

Related pages on this site

Background and Receptor Mechanism

Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.

At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.

Notes from published material

In rodents, the two major categories of mature mast cells are connective tissue-resident mast cells (CTMCs) and mucosal mast cells (MMCs). Connective tissue mast cells contain heparin and large amounts of histamine and carboxypeptidase in their granules, and are distributed in the skin, peritoneal cavity, intestinal submucosa, and perivascular space around blood vessels. Mucosal mast cells predominantly contain chondroitin sulfate with small amounts of histamine and carboxypeptidase and are distributed in the mucosa of the lung and gastrointestinal tract. CTMCs express high levels of mouse mast cell protease (mMCP)-4,-5 (chymases) and -6,-7 (tryptases), but not mMCP-1 and-2 (chymases), whereas MMCs express mMCP-1 and -2 and not mMCP-4,-5 and -6. In humans, three main categories of MCs have been identified based on the proteases they express. MCT expresses tryptase and resides primarily in mucosa of the lung and small intestine. MCTC expresses tryptase, chymase, and carboxypeptidase and resides primarily in the skin, lymph nodes, and lung and gut submucosa. ~98% of all mast cells in the mucosa of the human small intestine are MCT, while only ~13% of MCs in submucosa are MCT. A third form, MCC, expresses chymase but not tryptase. MCT somewhat resembles rodent MMC, while MCTC somewhat resembles rodent CTMC. Mast cells are still heterogenous within these main categories. In humans, at least six possible subsets of MCs with consistently expressed genes (or transcripts) have been observed across twelve organs.

Sedative drugs and sleeping pills, including lorazepam, have been associated with an increased risk of death. Sedation is the side effect people taking lorazepam most frequently report. In a group of around 3,500 people treated for anxiety, the most common side effects complained of from lorazepam were sedation (15.9%), dizziness (6.9%), weakness (4.2%), and unsteadiness (3.4%). Side effects such as sedation and unsteadiness increased with age. Cognitive impairment, behavioral disinhibition and respiratory depression as well as hypotension may also occur.

After the Dissolution of the Soviet Union in 1990, Cuba lost access to its primary financial partners, and was facing a massive economic collapse. In order to stave off the effects of economic isolation, they authorized the transformation of formerly state-owned enterprise into a new kind of joint private-public company to develop hotels and rejuvenate Cuba's tourism sector. The Communist Party of Cuba allowed Cuban civil society organizations to reform, allowing hundreds of non-governmental organizations to form in Havana, and especially relaxed its regulations on membership in Catholic Church. They relaxed regulations on international charities, including Caritas Internationalis. When the World Wide Web was created in 1991, Cuba authorized its citizens access to the internet. In 1991, the Congress of the Communist Party of Cuba officially authorized registered Communists to join the Freemasons (and churches). Membership in the Grand Lodge of Cuba rose sharply, and Cuba fully opened the country to Freemasonry. Masons were allowed to attend public events adorned in Masonic regalia. New lodges were opened across the country. Freemasons were also allowed to lay wreaths at the graves of deceased Brothers. After 1991, newly initiated Freemasons included high-ranking leaders of the Communist Party, government officials, members of Cuban dissident movements, antigovernment activists, and others. In 1993, Caridad del Rosario Diego Bello was appointed head of OAR.

Sources: en.wikipedia.org

Background from the literature

=== Attention deficit hyperactivity disorder === Atomoxetine is indicated for the treatment of attention deficit hyperactivity disorder (ADHD). It is approved for use in children, adolescents, and adults. However, its efficacy has not been studied in children under six years old. One of the primary differences with the standard stimulant treatments for ADHD is that it has no known misuse potential. Meta-analyses and systematic reviews have found that atomoxetine has comparable efficacy and equal tolerability to methylphenidate in children and adolescents. In adults, efficacy and tolerability are equivalent. The benefits of atomoxetine against ADHD symptoms are dose-dependent until a plateau is reached. While its efficacy may be less than that of lisdexamfetamine, there is some evidence supporting its use in combination with stimulants. Doctors may prescribe non-stimulants including atomoxetine when a person has bothersome side effects from stimulants; when a stimulant was not effective; in combination with a stimulant to increase effectiveness; when the cost of stimulants is prohibitive; or when there is concern about the misuse potential of stimulants in a patient with a history of substance use disorder. Atomoxetine, similarly to stimulants, appears to reduce emotional lability associated with ADHD in adults. Atomoxetine is thought to alleviate ADHD symptoms through norepinephrine reuptake inhibition and by indirectly increasing dopamine levels in the prefrontal cortex, sharing 70–80% of the brain regions with stimulants in its produced effects.

== Harvesting and processing == All ECM samples originate from mammalian tissues, such as dermis, pericardium, and small intestinal submucosa (SIS). After explantation from the source, the ECM biomaterial retains some characteristics of the original tissue. The ECM tissues can be harvested from varying stages in the developmental stages in mammalian species such as human, porcine, equine, and bovine. Although they are similarly composed of fibril collagen, the microstructure, specific composition (including presence of non-collagenous protein and glycosaminoglycans and ratio of different types of collagen), physical dimensions and mechanical properties can differ. Depending on the developmental stage of the tissue during which harvesting occurred, the microstructure can vary within an organism. Additionally, keeping in mind the size and shape of the final tissue, the potential of the physical dimensions of the tissue of origin must be considered. Despite this “memory” of the ECM tissue, methods have been engineered so that these innate characteristics can be modified, saved or removed. The modification process varies depending on the material used in clinical setting. Some ECM biomaterials undergo a modification that removes all the cells but leaves the remainder of the other ECM components called decellularization. Another process that can be introduced into the biomaterial is artificial crosslinking. Artificial crosslinking has been shown to stabilize reconstituted collagen, which can rapidly degenerate in vivo.

=== Common biochemistry === All known forms of life are based on the same fundamental biochemical organization: genetic information encoded in DNA, transcribed into RNA, through the effect of protein- and RNA-enzymes, then translated into proteins by (highly similar) ribosomes, with ATP, NADPH and others as energy sources. Analysis of small sequence differences in widely shared substances such as cytochrome c further supports universal common descent. Some 23 proteins are found in all organisms, serving as enzymes carrying out core functions like DNA replication. The fact that only one such set of enzymes exists is convincing evidence of a single ancestry. 6,331 genes common to all living animals have been identified; these may have arisen from a single common ancestor that lived 650 million years ago in the Precambrian.

q = ⁠1/2⁠ρv2 is dynamic pressure, h = z + ⁠p/ρg⁠ is the piezometric head or hydraulic head (the sum of the elevation z and the pressure head) and p0 = p + q is the stagnation pressure (the sum of the static pressure p and dynamic pressure q). The constant in the Bernoulli equation can be normalized. A common approach is in terms of total head or energy head H:

Sources: en.wikipedia.org

Further detail

== Disadvantages == Consistently producing ligand-targeted liposomes through traditional methods is difficult. The process can be tedious, challenging to control and result in a poorly defined system. Using the 'post-insertion' technique—in which Micelles formed from PEG-linked ligands are incubated with pre-formed, drug-loaded, non-targeted liposomes to combine and form LTLs—can limit the associated manufacturing challenges. When using certain ligands, such as antibodies, the risk for an immunological reaction poses a risk. Liposome design including size, charge, morphology, composition, surface characteristics, and dose size can all influence the immune response to administered LTLs. The ligands used can elicit an immune response when introduced into the body. For example, when peptide ligands such as CDX are used for brain-targeted delivery systems, they are immunogenic and trigger an immune response. Complement Activation-Related Pseudo-allergies (CARPA) is a hypersensitivity syndrome that can be triggered when LTLs activate the innate immune system and the complement system. CARPA can cause many side effects including anaphylaxis, cardiopulmonary distress, and facial swelling. These side effects have the potential to be severe, which generates concern when administering LTLs to patients with health problems, especially cardiovascular issues. This reaction can be reduced by slowing infusion rates or incorporating the use of allergy medicines like antihistamines into the treatment regimen.

Competition between RNA may have favored the emergence of cooperation between different RNA chains, opening the way for the formation of the first protocell. Eventually, RNA chains developed with catalytic properties that help amino acids bind together (a process called peptide-bonding). These amino acids could then assist with RNA synthesis, giving those RNA chains that could serve as ribozymes the selective advantage. The ability to catalyze one step in protein synthesis, aminoacylation of RNA, has been demonstrated in a short (five-nucleotide) segment of RNA. In 2014, a group of researchers managed to produce all four components of RNA by simulating an asteroid impact in primordial conditions. In March 2015, NASA scientists reported that, for the first time, complex DNA and RNA organic compounds of life, including uracil, cytosine, and thymine, have been formed in the laboratory under conditions found only in outer space, using starting chemicals, like pyrimidine, found in meteorites. Pyrimidine, like polycyclic aromatic hydrocarbons (PAHs), may have been formed in red giant stars or in interstellar dust and gas clouds, according to the scientists. That same month, researchers were able to produce over 50 aminoacids in a laboratory setting by using only hydrogen sulfide, hydrogen cyanide (presumably produced after outer space meteorites reacted with atmospheric nitrogen) and ultraviolet light.

== Legal status == It is scheduled as Class I drug in Canada. Class I classifications is for drugs that have no approved use in humans and poses a high risk for abuse. Carfentanil has been controlled in China since 1 March 2017. The China–United States trade war has included controversy over the effectiveness of this control. In Germany, carfentanil and its stereoisomers and salts are controlled by the Betäubungsmittelgesetz as a Anlage I substance and can only be used with the special permission of the authorities. Carfentanil is classified as Schedule II under the Controlled Substances Act in the United States with a DEA ACSCN of 9743 and a 2016 annual aggregate manufacturing quota of 19 grams (less than 0.7 oz.). Carfentanil requires approval from the Drug Enforcement Agency for veterinary use. Carfentanil has been specifically controlled as a Class A drug in the United Kingdom since 1986.

The New York Times wrote that Biden's "weak filters make him capable of blurting out pretty much anything". According to The New York Times, Biden often embellishes elements of his life or exaggerates, a trait also noted by The New Yorker in 2014. For instance, he has claimed to have been more active in the civil rights movement than he actually was, and has falsely recalled being an excellent student who earned three college degrees. The Times wrote, "Mr. Biden's folksiness can veer into folklore, with dates that don't quite add up and details that are exaggerated or wrong, the factual edges shaved off to make them more powerful for audiences."

=== As a refrigerant === Sulfur dioxide was one of the earliest refrigerants adopted for mechanical refrigeration owing to its ease of liquefaction and high latent heat of vaporization. In 1784, Jean-François Clouet and Gaspard Monge first demonstrated that sulfur dioxide gas could be liquefied at low temperatures. In the mid-1870s, Raoul Pictet successfully employed sulfur dioxide in a prototype refrigeration system. Beginning in 1920, it saw widespread use in the "Rollator" rotary-compressor home refrigerators produced by Norge. Following the introduction of less toxic, non-flammable chlorofluorocarbon (CFC) refrigerants, the use of sulfur dioxide in refrigeration systems gradually declined.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.

How does SR9009 differ from typical receptor agonists?

REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.

Has SR9009 been tested in humans?

Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.

What is SR9009?

SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.

Network